University of Oxford and Oracle Cloud System helping researchers identify COVID-19 variants faster

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research - New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

The Global Pathogen Analysis System is being provided as a free resource to help combat COVID-19 and other microbial health threats. Join the program and learn more at: www.gpas.cloud

Built using Oxford’s Scalable Pathogen Pipeline Platform (SP3), Oracle APEX, and Oracle Cloud Infrastructure(OCI), the Global Pathogen Analysis System is a cloud platform that provides a unified, standardized system for analyzing and comparing the annotated genomic sequence data of SARS-CoV-2. Researchers are using the system to upload pathogen data and receive comprehensive results within minutes. With user permission, the results may be shared with participating laboratories around the globe in a secure environment. Making this data comprehensible and shareable will help public health authorities evaluate and plan their response by giving them invaluable insight into emerging variants even before they are officially designated as Variants of Concern.

Uniting the global research community in a common mission

"GPAS is the first industry standards-based service anywhere in the world, offering a standardised sequence data analysis service for users on the cloud," said Derrick Crook, professor of microbiology in the University of Oxford's Nuffield Department of Medicine. "Users will be able to access, upload and process their sequence data fully under their sovereign control and receive back fully analysed data in as little as 20 minutes of successful upload. If they select to share data, they will contribute to electronic dashboard visualisations of global data revealing the daily changes in the way the pandemic is progressing and how the virus is changing. This will enable continuous assessment of the pandemic and help guide national and global interventions to curb the impact of the virus."

"COVID-19 is a global fight, yet researchers have lacked the technical infrastructure to process raw sequences quickly, securely and share those results worldwide," said Oracle Chairman and CTO, Larry Ellison. "With GPAS, we are bringing the power and security of the cloud to enable any researcher, in any location to become part of the solution. The more data that medical institutions, governments, and academics provide, the more quickly we can understand and act to get ahead of the coronavirus."

Using the platform, researchers and governments will be able to quickly access the timely, relevant data they need to make up-to-date scientific analysis and better informed policy and safety decisions regarding new variants. As part of their work with the Global Health Security Consortium (GHSC), the Lawrence J. Ellison Institute for Transformative Medicine (Ellison Institute) and the Tony Blair Institute (TBI) for Global Change have worked in coordination with Oxford and Oracle to support the development of the platform and to get it in the hands of global researchers.

"The world's lack of preparedness for the COVID-19 pandemic has highlighted our need to work differently in order to identify solutions that are pragmatic and able to scale in the face of challenges," said Dr. David B. Agus, GHSC Member and CEO, Ellison Institute. "GPAS is a key building block in the global data infrastructure for early warning systems and global surveillance."

"We know only too well that viruses do not respect borders which is why we must take a global, single-minded approach to contain this pandemic," said Tony Blair, Executive Chairman of TBI and former UK Prime Minister. "This platform promises to bring together data much more rapidly, helping us to better understand and get ahead of the patterns of spread faster, so governments can make better policy decisions and mitigate the devastating impact this virus continues to inflict in their own countries and across the globe."

To get involved in this initiative, please visit: www.gpas.cloud

About the University of Oxford

The University of Oxford has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation.

Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.

Through its research commercialization arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years.

About Oracle

Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud.

About the Global Health Security Consortium

The Global Health Security Consortium (GHSC) provides insight, analysis and support for leaders around the world to help them deal with COVID-19 today and prepare for the health security challenges of tomorrow. It is a joint initiative of the Tony Blair Institute for Global Change, the Ellison Institute for Transformative Medicine, and a team of scientists at the University of Oxford.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...